safeguard scientifics q4 and fy'11 results presentation

16
SFE Fourth Quarter and Full-Year 2011 Results

Upload: safeguard-scientifics

Post on 30-Nov-2014

1.067 views

Category:

Economy & Finance


3 download

DESCRIPTION

Safeguard Scientifics Announces Fourth Quarter and Full-Year 2011 Financial Results For the complete Q4 and FY'11 Press release, click here: http://www.safeguard.com/safeguard-scientifics-announces-fourth-quarter-and-full-year-2011-financial-results Forward-Looking Statements Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, our ability to execute our strategy, the uncertainty of the future performance of our partner companies, acquisitions and dispositions of additional partner companies, the inability to manage growth, government regulation and legal liabilities and the effect of economic conditions in the business sectors in which our partner companies operate, negative media coverage and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation.

TRANSCRIPT

Page 1: Safeguard Scientifics Q4 and FY'11 Results Presentation

SFE Fourth Quarter and Full-Year 2011 Results

Page 2: Safeguard Scientifics Q4 and FY'11 Results Presentation

22

Forward Looking Statements

Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, our ability to execute our strategy, the uncertainty of the future performance of our partner companies, acquisitions and dispositions of additional partner companies, the inability to manage growth, government regulation and legal liabilities and the effect of economic conditions in the business sectors in which our partner companies operate, negative media coverage and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation.

Page 3: Safeguard Scientifics Q4 and FY'11 Results Presentation

33

Safeguard 2011 Highlights

• Well-Timed Exits in 2011– Net Proceeds, Including Escrow, of $182M

– Cash-on-Cash Returns of 4x and 14x

• Capital Deployment– $69M in Seven New Companies; Three Follow-on Transactions for $14M

• Partner Company Aggregate Revenue of $140.0M

• Penn Mezzanine Launched

• Total Debt to Equity of 1:8

Page 4: Safeguard Scientifics Q4 and FY'11 Results Presentation

44

Safeguard Strategy

• Exploit Five Strategic Themes– Maturity, Migration, Convergence, Compliance and Cost Containment

• Typically Deploy up to $25M in Growth Capital per Partner Company

• 17 Partner Companies Today

• Exits Timed to Maximize Risk-Adjusted Returns on Capital– Targeted Aggregate 2x to 4x, at a Minimum, Given Evolving Diversified

Deployment Strategy

– Aggregate 2.4x Cash-on-Cash Return since 2006

Page 5: Safeguard Scientifics Q4 and FY'11 Results Presentation

55

• Revolutionary Offering in Usage-Based Insurance (UBI) Market

• Initial Revenue Stage

• U.S. Market for UBI Could Grow to 55M Subscribers

• SFE Deployed $1.7M in Series A-1 Financing

• 24% Primary Ownership

• Sales Performance Optimization Platform

• Initial Revenue Stage

• Enterprise Gamification Market is Growing Rapidly

• SFE Deployed $1.3M in Series A Financing

• 25% Primary Ownership

New Partner Companies

Page 6: Safeguard Scientifics Q4 and FY'11 Results Presentation

66

New Partner Companies

• Robust Visualization and Analytical Tools for Fixed Income Marketplace

• Initial Revenue Stage• Product DIVER offers 130+ Data Sets from 30+ Sources• SFE Deployed $2.2M in Series A Financing• 32% Primary Ownership

Page 7: Safeguard Scientifics Q4 and FY'11 Results Presentation

77

• Healthcare IT Company that Provides Data Analytics and Lab Testing Services via the Internet

• Initial Revenue Stage

• 1.4M Tests were Ordered through Medivo in 2011

• SFE Deployed $6.3M in Series A Financing

• 30% Primary Ownership

• Advertising Technology Company

• Expansion Stage

• Display Ads Expected to be a $27B Industry Globally in 2016

• SFE Deployed $10M in Series B Financing

• 23% Primary Ownership

New Partner Companies

Page 8: Safeguard Scientifics Q4 and FY'11 Results Presentation

88

Current Partner Companies

• Strong Growth Continues

• Home Sleep Test Reduces Diagnostic Costs by Two-Thirds as Compared to Sleep Labs

• Industry Veteran, Brett H. Craig, Named President and CEO (Former President & COO of Transitions Optical)

• Development Pipeline Expected to Swell

Page 9: Safeguard Scientifics Q4 and FY'11 Results Presentation

99

• $64.2M Total Funding• 7 Investments as of 12/31/11• $26.4M Invested; SFE is GP and Co-Investor• All Maturities ≤ 5 Years from Funding• Yielding 13.3% • Does Not Include Any Equity Appreciation

2011 Highlights

Page 10: Safeguard Scientifics Q4 and FY'11 Results Presentation

1010

Why Own Safeguard?

• Value Realized by Developing Growth-Stage Businesses through Active Ownership

• Healthy Portfolio of Well-Positioned Partner Companies

• Major Improvements in Financial Strength, Flexibility and Liquidity

• Initiatives to Increase Capital Under Management

• Strong Alignment of Interests

Page 11: Safeguard Scientifics Q4 and FY'11 Results Presentation

1111

Holdings as of December 31, 2011

Acquisition Year

Ownership %

Carrying Value Cost

Life Sciences Partner Companies:Alverix 2007 50% 0.3 7.7 Good Start Genetics 2010 26% 4.4 6.8 Medivo 2011 30% 6.3 6.3 NovaSom 2011 30% 17.9 20.0 NuPathe (Nasdaq: PATH) 2006 18% 4.9 18.3 PixelOptics 2011 25% 20.3 25.0 Putney 2011 28% 9.9 10.0

TOTAL: 64.0 94.1

Technology:AdvantEdge Healthcare Solutions 2006 40% 7.8 15.3 Beyond.com 2007 38% 10.7 13.5 Bridgevine 2007 23% 6.4 10.0 Crimson Informatics 2011 24% 1.7 1.7 Hoopla Software 2011 28% 1.3 1.3 MediaMath 2009 22% 13.8 16.9 Swap.com 2008 46% - 10.5 ThingWorx 2011 30% 4.0 5.0

TOTAL: 45.7 74.2

Total: Life Sciences + Technology 109.7$ 168.3$

Figures above do not include $13.6M deployed relating to Penn Mezzanine in 2011 or amounts previously deployed in private equity funds.

Page 12: Safeguard Scientifics Q4 and FY'11 Results Presentation

1212

Financial Highlights

• Net Cash, Cash Equivalents and Marketable Securities

– $258M at 12/31/11 vs. $226M at 12/31/10

• 2011 Primary Uses of Cash = $145M

• 2012 Projected Uses of Cash = $100M to $150M

– Corporate Expenses

– Capital Deployment into New Partner Companies

– Follow-on Funding for Current Partner Companies and Penn Mezzanine Participations

– Platform Expansion

Page 13: Safeguard Scientifics Q4 and FY'11 Results Presentation

1313

Safeguard Partner Companies

* Aggregate revenue guidance for 2012 and prior years, presented above, reflects revenue on a net basis. Revenue figures utilized for certain companies pertain to periods prior to Safeguard’s involvement with said companies and based solely on information provided to Safeguard by such companies. Safeguard reports the revenue of its equity method and cost method partner companies on a one-quarter lag basis.

• 17 Partner Companies Today

• 27 Board Seats Across 17 Companies

• 16 Companies Generating Revenue

• 4 Companies EBITDA Positive

• 1 Company Filed NDA

• Deployed $181M in Current Partner Companies

• Realized $632M Since January 2006 (2.4x CoC)

• Strong Partner Company Satisfaction

Aggregate Revenue*

Page 14: Safeguard Scientifics Q4 and FY'11 Results Presentation

Questions & Answers

Page 15: Safeguard Scientifics Q4 and FY'11 Results Presentation

1515

Why Own Safeguard?

• Value Realized by Developing Growth-Stage Businesses through Active Ownership

• Healthy Portfolio of Well-Positioned Partner Companies

• Major Improvements in Financial Strength, Flexibility and Liquidity

• Initiatives to Increase Capital Under Management

• Strong Alignment of Interests

Page 16: Safeguard Scientifics Q4 and FY'11 Results Presentation

Replay Information855-859-2056

(International) +404-537-3406Replay available through March 30, 2012 at 11:59 pm EDT